FREMONT, Calif., Sept. 14, 2016 /PRNewswire/ -- WaferGen
Bio-systems, Inc. (Nasdaq: WGBS) presented T-cell receptor (TCR)
sequencing results from its ICELL8™ Single-Cell System at the
Single Cell Genomics Conference in Cambridge, United Kingdom. The poster
presentation, titled "A SMARTer® Approach to Profiling the Human
T-cell Receptor Repertoire Using the ICELL8 Single Cell System",
demonstrates the ability to perform TCR sequencing from thousands
of single cells and is a joint poster with Takara Bio USA, Inc. (formerly known as Clontech
Laboratories, Inc.).
Results presented using the ICELL8 Single-Cell system display
the power of high throughput single-cell TCR sequencing analysis.
Analysis was performed using more than 1,000 single Jurkat cells
which were isolated, automatically identified and selected using
proprietary CellSelect™ software and prepared for next generation
sequencing analysis. Individual TCR sequences from each cell
(clonotypes) were selectively amplified and sequenced in a MiSeq
using 2 x 300 base pair sequencing. Single-cell TCR sequencing
analysis revealed the expected clonotypes and the total number of
clonotypes identified correlated with equivalent bulk samples.
Single-cell analysis was also able to provide greater insights by
identifying paired alpha and beta subunit information, which is not
possible using bulk samples.
"The ICELL8 Single-Cell system is a powerful and flexible
technology platform which can enable a number of new, high
throughput single-cell applications. TCR sequencing at the single
cell level will provide greater insights for researchers in the
biotech and pharma community working on solutions for
immuno-oncology, immune deficiency, autoimmunity, and vaccine
response," said Rollie Carlson,
President and CEO of WaferGen. "The TCR sequencing application is
also the first demonstration of the synergies that we expect from
the partnership between WaferGen Bio-systems and Takara Bio
USA."
The ICELL8 Single-Cell System can be used to isolate thousands
of single cells and prepare them for next generation sequencing
analysis. The system has been used to successfully process a wide
range of cell types, including live single neurons, human tumor
cells, mouse tumor cells, T-cells and nuclei, demonstrating
effective and unbiased cell isolation. The system also runs up to
eight samples of various cell types and sizes on a single chip. The
system was initially developed for 3' RNA sequencing applications
but additional applications, such as TCR sequencing, can be easily
deployed.
About WaferGen
WaferGen Bio-systems, Inc. is a biotechnology company that
offers innovative genomic technology solutions for single-cell
analysis and clinical research. The ICELL8™ Single-Cell System is a
first of its kind system that can isolate thousands of single cells
and processes specific cells for analysis, including NGS. The
system has demonstrated unbiased isolation of single cells from
solid tumors, brain cells, pulmonary airway cells, and multiple
cell lines. The SmartChip™ platform can be used for profiling and
validating molecular biomarkers, and can perform massively-parallel
singleplex PCR for one-step target enrichment and library
preparation for clinical NGS. The Apollo 324™ system can be used to
process DNA and RNA from clinical samples to NGS-ready libraries.
These technologies offer a powerful set of tools for biological
analysis at the molecular and single-cell level in the life
sciences, pharmaceutical, and clinical laboratory industries.
WaferGen recently announced a merger agreement with Takara Bio Inc.
(TSE: 4974), a leading Japanese and global biotechnology and life
science reagents company, which is expected to close in March of
2017.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor"
created by those sections. Forward-looking statements, which are
based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of forward-looking terms such as "believe," "expect," "may,"
"will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms. Forward-looking statements
in this press release may address the following subjects among
others: statements regarding the closing of the merger agreement
with Takara Bio Inc., sufficiency of our capital resources,
expected operating losses, expected revenues, expected expenses,
expected cash usage, our expectations regarding our development of
future products including single cell analysis technologies and our
expectations concerning our competitive position and business
strategy. Forward-looking statements involve inherent risks and
uncertainties which could cause actual results to differ materially
from those in the forward-looking statements, as a result of
various factors including those risks and uncertainties described
in the Risk Factors and in Management's Discussion and Analysis of
Financial Condition and Results of Operations sections of our most
recently filed Annual Report on Form 10-K and any subsequently
filed Quarterly Reports on Form 10-Q. We urge you to consider those
risks and uncertainties in evaluating our forward-looking
statements. We caution readers not to place undue reliance upon any
such forward-looking statements, which speak only as of the date
made. Except as otherwise required by the federal securities laws,
we disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
Investor Contact:
Rollie Carlson
Rollie.Carlson@wafergen.com
510-277-3417
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wafergen-presents-single-cell-t-cell-receptor-sequencing-results-using-the-icell8-single-cell-system-at-the-2016-single-cell-genomics-meeting-300327741.html
SOURCE WaferGen Bio-systems, Inc.